Amphastar Pharmaceuticals (AMPH) Current Deferred Revenue (2013 - 2016)

Amphastar Pharmaceuticals has reported Current Deferred Revenue for 4 years, with the latest figure at $830000.0 in Q3 2016.

• On a quarterly basis, Current Deferred Revenue rose 29.08% year-over-year to $830000.0 in Q3 2016; TTM through Sep 2016 was $830000.0, a 29.08% increase from a year earlier, with the FY2015 full-year figure at $643000.0, down 95.41% from the prior year.
• Current Deferred Revenue was $830000.0 for Q3 2016 at Amphastar Pharmaceuticals, down from $1.7 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $14.6 million in Q3 2014, with the low at $643000.0 in Q4 2013.
• Average Current Deferred Revenue over 4 years is $4.1 million, with a median of $830000.0 recorded in 2016.
• The sharpest annual moves came in 2014 and 2015: Current Deferred Revenue soared 2079.32% in 2014, then tumbled 95.59% in 2015.
• Over 4 years, Current Deferred Revenue stood at $643000.0 in 2013, then jumped by 2079.32% to $14.0 million in 2014, then tumbled by 95.41% to $643000.0 in 2015, then rose by 29.08% to $830000.0 in 2016.
• The last three Current Deferred Revenue figures came in at $830000.0 (Q3 2016), $1.7 million (Q2 2016), and $643000.0 (Q1 2016), per Business Quant data.